<p>DBV Technologies S.A.（NASDAQ:DBVT - 获取免费报告）在周五的交易中，其股价突破了 50 日移动平均线。该股票的 50 日移动平均线为 21.20 美元，最高交易价为 21.24 美元。DBV Technologies 的股票最后交易价为 20.59 美元，成交量为 181,986 股。</p>
<p>获取 <strong>DBV Technologies</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>3 只生物制药股票逆势而上</li>
</ul>
<p>DBVT 已成为多份分析师报告的主题。Citizens Jmp 在 3 月 27 日的研究报告中将 DBV Technologies 的目标价从 45.00 美元上调至 47.00 美元，并给予该公司 “市场表现优于大盘” 的评级。华尔街 Zen 在 3 月 28 日的报告中将 DBV Technologies 的评级从 “持有” 下调至 “卖出”。花旗集团在 12 月 17 日的报告中重申了对 DBV Technologies 股票的 “跑赢大盘” 评级。Guggenheim 在 3 月 27 日的报告中重申了 “买入” 评级，并对 DBV Technologies 的股票设定了 51.00 美元的目标价。最后，Cantor Fitzgerald 在 12 月 17 日的报告中设定了 48.00 美元的目标价。两位分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 38.65 美元。</p>
<p><strong>阅读我们关于 DBV Technologies 的最新报告</strong></p>
<h2>DBV Technologies 价格表现</h2>
<p>该公司的市值为 11.5 亿美元，市盈率为-3.94，贝塔值为-0.94。该股票的 50 日简单移动平均线为 21.20 美元，200 日简单移动平均线为 17.99 美元。</p>
<p>DBV Technologies（NASDAQ:DBVT - 获取免费报告）最近在 2 月 14 日发布了季度财报。该公司报告每股收益（EPS）为-1.15 美元。DBV Technologies 的股本回报率为-189.17%，净利润率为-2,606.83%。该业务在本季度的收入为 65 万美元。分析师平均预测 DBV Technologies S.A.在当前年度的每股收益为-7.05 美元。</p>
<h2>DBV Technologies 的机构交易</h2>
<p>一些大型投资者最近调整了对 DBVT 的持股。Artisan Partners Limited Partnership 在第四季度将其在 DBV Technologies 的股份增加了 6,273.4%。Artisan Partners Limited Partnership 现在拥有 3,309,055 股该公司的股票，价值 63,435,000 美元，此前在上个季度购买了 3,257,135 股。Vivo Capital LLC 在第四季度将其在 DBV Technologies 的持股增加了 133.4%。Vivo Capital LLC 现在拥有 2,461,626 股该公司的股票，价值 47,189,000 美元，此前在上个季度购买了 1,407,120 股。Siren L.L.C.在第四季度购买了 DBV Technologies 的新头寸，价值为 35,606,000 美元。Adage Capital Partners GP L.L.C.在第二季度购买了 DBV Technologies 的新头寸，价值为 9,659,000 美元。最后，MPM Bioimpact LLC 在第二季度购买了 DBV Technologies 的新头寸，价值为 9,649,000 美元。对冲基金和其他机构投资者持有该公司 71.74% 的股票。</p>
<h2>关于 DBV Technologies</h2>
<p>（获取免费报告）</p>
<p>DBV Technologies SA 是一家临床阶段的生物制药公司，专注于开发过敏性疾病的免疫疗法。该公司专注于皮肤免疫疗法，利用其专有的 Viaskin 平台通过完整的皮肤传递生物活性化合物，无需针头或注射。通过这种方法，DBV 旨在调节患者对特定过敏原的免疫反应，提供一种潜在更安全、更便捷的替代传统疗法的选择。</p>
<p>该公司的主要产品候选药物 Viaskin Peanut 旨在治疗儿童和青少年的花生过敏。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票超过 DBV Technologies</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 DBV Technologies 吗？</h2>
<p>在你考虑 DBV Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 DBV Technologies 并不在名单上。</p>
<p>虽然 DBV Technologies 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

DBV 科技

纽交所高增长板生物技术指数 ETF - First Trust

<p>DBV Technologies（纳斯达克代码：DBVT）股票价格已突破其 50 日移动均线 21.20 美元，目前交易价格为 20.59 美元，成交量为 181,986 股。分析师的评级不一，目标价格范围在 45 美元到 51 美元之间。该公司报告的每股收益为负值（1.15 美元），市值为 11.5 亿美元。机构投资者持有 71.74% 的股份。DBV Technologies 专注于开发针对过敏性疾病的免疫疗法，特别是其主要产品候选药物 Viaskin Peanut，旨在治疗儿童的花生过敏</p>

<p>DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $21.20 and traded as high as $21.24. DBV Technologies shares last traded at $20.59, with a volume of 181,986 shares changing hands.</p>
<div class="lb-trans"><p>DBV Technologies S.A.（NASDAQ:DBVT - 获取免费报告）在周五的交易中，其股价突破了 50 日移动平均线。该股票的 50 日移动平均线为 21.20 美元，最高交易价为 21.24 美元。DBV Technologies 的股票最后交易价为 20.59 美元，成交量为 181,986 股。</p>
</div><p>Get <strong>DBV Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>DBV Technologies</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物制药股票逆势而上</li>
</ul>
</div><p>DBVT has been the topic of several analyst reports. Citizens Jmp lifted their target price on DBV Technologies from $45.00 to $47.00 and gave the company a &#34;market outperform&#34; rating in a research note on Friday, March 27th. Wall Street Zen lowered shares of DBV Technologies from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, March 28th. Citigroup reaffirmed an &#34;outperform&#34; rating on shares of DBV Technologies in a report on Wednesday, December 17th. Guggenheim reaffirmed a &#34;buy&#34; rating and issued a $51.00 price target on shares of DBV Technologies in a report on Friday, March 27th. Finally, Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $38.65.</p>
<div class="lb-trans"><p>DBVT 已成为多份分析师报告的主题。Citizens Jmp 在 3 月 27 日的研究报告中将 DBV Technologies 的目标价从 45.00 美元上调至 47.00 美元，并给予该公司 “市场表现优于大盘” 的评级。华尔街 Zen 在 3 月 28 日的报告中将 DBV Technologies 的评级从 “持有” 下调至 “卖出”。花旗集团在 12 月 17 日的报告中重申了对 DBV Technologies 股票的 “跑赢大盘” 评级。Guggenheim 在 3 月 27 日的报告中重申了 “买入” 评级，并对 DBV Technologies 的股票设定了 51.00 美元的目标价。最后，Cantor Fitzgerald 在 12 月 17 日的报告中设定了 48.00 美元的目标价。两位分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 38.65 美元。</p>
</div><p><strong>Read Our Latest Report on DBV Technologies</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 DBV Technologies 的最新报告</strong></p>
</div><h2>DBV Technologies Price Performance</h2>
<div class="lb-trans"><h2>DBV Technologies 价格表现</h2>
</div><p>The company has a market capitalization of $1.15 billion, a PE ratio of -3.94 and a beta of -0.94. The stock's 50 day simple moving average is $21.20 and its 200-day simple moving average is $17.99.</p>
<div class="lb-trans"><p>该公司的市值为 11.5 亿美元，市盈率为-3.94，贝塔值为-0.94。该股票的 50 日简单移动平均线为 21.20 美元，200 日简单移动平均线为 17.99 美元。</p>
</div><p>DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share (EPS) for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The business had revenue of $0.65 million for the quarter. On average, equities analysts predict that DBV Technologies S.A. will post -7.05 earnings per share for the current year.</p>
<div class="lb-trans"><p>DBV Technologies（NASDAQ:DBVT - 获取免费报告）最近在 2 月 14 日发布了季度财报。该公司报告每股收益（EPS）为-1.15 美元。DBV Technologies 的股本回报率为-189.17%，净利润率为-2,606.83%。该业务在本季度的收入为 65 万美元。分析师平均预测 DBV Technologies S.A.在当前年度的每股收益为-7.05 美元。</p>
</div><h2>Institutional Trading of DBV Technologies</h2>
<div class="lb-trans"><h2>DBV Technologies 的机构交易</h2>
</div><p>A number of large investors have recently modified their holdings of DBVT. Artisan Partners Limited Partnership increased its stake in DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company's stock valued at $63,435,000 after purchasing an additional 3,257,135 shares during the last quarter. Vivo Capital LLC grew its holdings in shares of DBV Technologies by 133.4% during the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company's stock worth $47,189,000 after buying an additional 1,407,120 shares during the last quarter. Siren L.L.C. purchased a new position in DBV Technologies in the 4th quarter valued at $35,606,000. Adage Capital Partners GP L.L.C. purchased a new position in DBV Technologies in the 2nd quarter valued at $9,659,000. Finally, MPM Bioimpact LLC purchased a new position in DBV Technologies in the 2nd quarter valued at $9,649,000. Hedge funds and other institutional investors own 71.74% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对 DBVT 的持股。Artisan Partners Limited Partnership 在第四季度将其在 DBV Technologies 的股份增加了 6,273.4%。Artisan Partners Limited Partnership 现在拥有 3,309,055 股该公司的股票，价值 63,435,000 美元，此前在上个季度购买了 3,257,135 股。Vivo Capital LLC 在第四季度将其在 DBV Technologies 的持股增加了 133.4%。Vivo Capital LLC 现在拥有 2,461,626 股该公司的股票，价值 47,189,000 美元，此前在上个季度购买了 1,407,120 股。Siren L.L.C.在第四季度购买了 DBV Technologies 的新头寸，价值为 35,606,000 美元。Adage Capital Partners GP L.L.C.在第二季度购买了 DBV Technologies 的新头寸，价值为 9,659,000 美元。最后，MPM Bioimpact LLC 在第二季度购买了 DBV Technologies 的新头寸，价值为 9,649,000 美元。对冲基金和其他机构投资者持有该公司 71.74% 的股票。</p>
</div><h2>About DBV Technologies</h2>
<div class="lb-trans"><h2>关于 DBV Technologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.</p>
<div class="lb-trans"><p>DBV Technologies SA 是一家临床阶段的生物制药公司，专注于开发过敏性疾病的免疫疗法。该公司专注于皮肤免疫疗法，利用其专有的 Viaskin 平台通过完整的皮肤传递生物活性化合物，无需针头或注射。通过这种方法，DBV 旨在调节患者对特定过敏原的免疫反应，提供一种潜在更安全、更便捷的替代传统疗法的选择。</p>
</div><p>The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 Viaskin Peanut 旨在治疗儿童和青少年的花生过敏。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than DBV Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 DBV Technologies</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DBV Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 DBV Technologies 吗？</h2>
</div><p>Before you consider DBV Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 DBV Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 DBV Technologies 并不在名单上。</p>
</div><p>While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 DBV Technologies 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

DBV Technologies（纳斯达克股票代码：DBVT）股价突破 50 日移动平均线 - 以下是原因